Inhibition of Eukaryotic Translation by the Antitumor Natural Product Agelastatin A

Cell Chemical Biology

Volumn 24, Issue 5, 2017, Pages 605-613.e5

  McClary, Brandon ^a   Zinshteyn, Boris ^a   Meyer, Mélanie ^b   Jouanneau, Morgan ^c   Pellegrino, Simone ^b   Yusupova, Gulnara ^b   Schuller, Anthony ^a   Reyes, Jeremy Chris P ^f   Lu, Junyan ^d   Guo, Zufeng ^a   Ayinde, Safiat ^a   Luo, Cheng ^d   Dang, Yongjun ^e   Romo, Daniel ^c   Yusupov, Marat ^b   Green, Rachel ^a   Liu, Jun O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c BAYLOR UNIVERSITY   (United States)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^e FUDAN UNIVERSITY   (China)

^f TEXAS A AND M UNIVERSITY   (United States)

Author keywords

agelastatin A; brain cancer; chemical footprinting; drug design; marine alkaloid; molecular docking; peptidyl transferase center; ribosome; rRNA seq; translation elongation

Indexed keywords

AGELASTATIN A; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; ALKALOID; BIOLOGICAL PRODUCT; OXAZOLIDINONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RIBOSOME; RIBOSOME SUBUNIT; TRANSLATION ELONGATION; DOSE RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; PROTEIN CONFORMATION;

ALKALOIDS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MOLECULAR DOCKING SIMULATION; OXAZOLIDINONES; PROTEIN BIOSYNTHESIS; PROTEIN CONFORMATION; RIBOSOMES;

EID: 85018190156     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.04.006     Document Type: Article

References (50)

1. Abid, M.R., Li, Y., Anthony, C., De Benedetti, A., Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E Links protein synthesis to the control of DNA replication. J. Biol. Chem. 274 (1999), 35991–35998.
2. Acker, M.G., Kolitz, S.E., Mitchell, S.F., Nanda, J.S., Lorsch, J.R., Reconstitution of yeast translation initiation. Methods Enzymol. 430 (2007), 111–145.
3. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 213–221.
4. Ben-Shem, A., Garreau de Loubresse, N., Melnikov, S., Jenner, L., Yusupova, G., Yusupov, M., The structure of the eukaryotic ribosome at 3.0 A resolution. Science 334 (2011), 1524–1529.
5. Berthon, J., Fujikane, R., Forterre, P., When DNA replication and protein synthesis come together. Trends Biochem. Sci. 34 (2009), 429–434.
6. Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., Topisirovic, I., Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14 (2015), 261–278.
7. Brunelle, J.L., Shaw, J.J., Youngman, E.M., Green, R., Peptide release on the ribosome depends critically on the 2’ OH of the peptidyl-tRNA substrate. RNA 14 (2008), 1526–1531.
8. Chan, J., Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles. RNA 10 (2004), 528–543.
9. Chen, V.B., Arendall, W.B. 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W., Richardson, J.S., Richardson, D.C., MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66 (2010), 12–21.
10. Cragg, G.M., Grothaus, P.G., Newman, D.J., Impact of natural products on developing new anti-cancer agents. Chem. Rev. 109 (2009), 3012–3043.
11. D'Ambrosio, M., Guerriero, A., Debitus, C.c., Ribes, O., Pusset, J., Leroy, S., Pietra, F., Agelastatin a, a new skeleton cytotoxic alkaloid of the oroidin family. Isolation from the axinellid sponge Agelas dendromorpha of the coral sea. J. Chem. Soc. Chem. Comm, 1993, 1305.
12. Dang, Y., Kedersha, N., Low, W.K., Romo, D., Gorospe, M., Kaufman, R., Anderson, P., Liu, J.O., Eukaryotic initiation factor 2alpha-independent pathway of stress granule induction by the natural product pateamine A. J. Biol. Chem. 281 (2006), 32870–32878.
13. Dang, Y., Schneider-Poetsch, T., Eyler, D.E., Jewett, J.C., Bhat, S., Rawal, V.H., Green, R., Liu, J.O., Inhibition of eukaryotic translation elongation by the antitumor natural product Mycalamide B. RNA 17 (2011), 1578–1588.
14. Ding, Y., Tang, Y., Kwok, C.K., Zhang, Y., Bevilacqua, P.C., Assmann, S.M., In vivo genome-wide profiling of RNA secondary structure reveals novel regulatory features. Nature 505 (2013), 696–700.
15. Dong, G., Recent advances in the total synthesis of agelastatins. Pure Appl. Chem. 82 (2010), 2231–2246.
16. Emsley, P., Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004), 2126–2132.
17. Eyler, D.E., Green, R., Distinct response of yeast ribosomes to a miscoding event during translation. RNA 17 (2011), 925–932.
18. Gandhi, V., Plunkett, W., Cortes, J.E., Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin. Cancer Res. 20 (2014), 1735–1740.
19. Garreau de Loubresse, N., Prokhorova, I., Holtkamp, W., Rodnina, M.V., Yusupova, G., Yusupov, M., Structural basis for the inhibition of the eukaryotic ribosome. Nature 513 (2014), 517–522.
20. Han, S., Siegel, D.S., Morrison, K.C., Hergenrother, P.J., Movassaghi, M., Synthesis and anticancer activity of all known (−)-Agelastatin alkaloids. J. Org. Chem. 78 (2013), 11970–11984.
21. Homan, P.J., Favorov, O.V., Lavender, C.A., Kursun, O., Ge, X., Busan, S., Dokholyan, N.V., Weeks, K.M., Single-molecule correlated chemical probing of RNA. Proc. Natl. Acad. Sci. USA 111 (2014), 13858–13863.
22. Jackson, R.J., Hellen, C.U.T., Pestova, T.V., The mechanism of eukaryotic translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 11 (2010), 113–127.
23. Jouanneau, M., McClary, B., Reyes, J.C.P., Chen, R., Chen, Y., Plunkett, W., Cheng, X., Milinichik, A.Z., Albone, E.F., Liu, J.O., et al. Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe. Bioorg. Med. Chem. Lett. 26 (2016), 2092–2097.
24. Kabsch, W., Integration, scaling, space-group assignment and post-refinement. Acta Cryst. D66 (2010), 133–144.
25. Kapp, L.D., Lorsch, J.R., The molecular mechanics of eukaryotic translation. Annu. Rev. Biochem. 73 (2004), 657–704.
26. Kuznetsov, G., Xu, Q., Rudolph-Owen, L., Tendyke, K., Liu, J., Towle, M., Zhao, N., Marsh, J., Agoulnik, S., Twine, N., et al. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol. Cancer Ther. 8 (2009), 1250–1260.
27. Li, Z., Shigeoka, D., Caulfield, T.R., Kawachi, T., Qiu, Y., Kamon, T., Arai, M., Tun, H.W., Yoshimitsu, T., An integrated approach to the discovery of potent agelastatin A analogues for brain tumors: chemical synthesis and biological, physicochemical and CNS pharmacokinetic analyses. MedChemComm, 4, 2013, 1093.
28. Low, W.K., Dang, Y., Schneider-Poetsch, T., Shi, Z., Choi, N.S., Merrick, W.C., Romo, D., Liu, J.O., Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol. Cell 20 (2005), 709–722.
29. Mason, C.K., McFarlane, S., Johnston, P.G., Crowe, P., Erwin, P.J., Domostoj, M.M., Campbell, F.C., Manaviazar, S., Hale, K.J., El-Tanani, M., Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol. Cancer Ther. 7 (2008), 548–558.
30. Meijer, L., Thunnissen, A.M., White, A., Garnier, M., Nikolic, M., Tsai, L.H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.Z., et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7 (2000), 51–63.
31. Moazed, D., Stern, S., Noller, H.F., Rapid chemical probing of conformation in 16 S ribosomal RNA and 30 S ribosomal subunits using primer extension. J. Mol. Biol. 187 (1986), 399–416.
32. Moen, M.D., McKeage, K., Plosker, G.L., Siddiqui, M.A.A., Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 67 (2007), 299–320.
33. Movassaghi, M., Siegel, D.S., Han, S., Total synthesis of all (-)-Agelastatin alkaloids. Chem. Sci. 1 (2010), 561–566.
34. Newman, D.J., Cragg, G.M., Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79 (2016), 629–661.
35. Oguro, M., Suzuki-Hori, C., Nagano, H., Mano, Y., Ikegami, S., The mode of inhibitory action by aphidicolin on eukaryotic DNA polymerase alpha. Eur. J. Biochem. 97 (1979), 603–607.
36. Pestova, T.V., Shatsky, I.N., Fletcher, S.P., Jackson, R.J., Hellen, C.U., A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev. 12 (1998), 67–83.
37. Pettit, G.R., Ducki, S., Herald, D.L., Doubek, D.L., Schmidt, J.M., Chapuis, J.C., Antineoplastic agents 470. Absolute configuration of the marine sponge bromopyrrole agelastatin A. Oncol. Res. 15 (2005), 11–20.
38. Pfeffer, S.ï.b., Lagos-Quintana, M., Tuschl, T., Cloning of small RNA molecules. Curr. Protoc. Mol. Biol., 2005 Chapter 26, Unit 26.4.
39. Reid, S.A., Nyambo, S., Muzangwa, L., Uhler, B., pi-Stacking, C-H/pi, and halogen bonding interactions in bromobenzene and mixed bromobenzene-benzene clusters. J. Phys. Chem. A 117 (2013), 13556–13563.
40. Reyes, J.C.P., Romo, D., Bioinspired total synthesis of agelastatin A. Angew. Chem. Int. Ed 51 (2012), 6870–6873.
41. Rodriguez-Fonseca, C., Amils, R., Garrett, R.A., Fine structure of the peptidyl transferase centre on 23 S-like rRNAs deduced from chemical probing of antibiotic-ribosome complexes. J. Mol. Biol. 247 (1995), 224–235.
42. Rouskin, S., Zubradt, M., Washietl, S., Kellis, M., Weissman, J.S., Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo. Nature 505 (2013), 701–705.
43. Schneider-Poetsch, T., Ju, J., Eyler, D.E., Dang, Y., Bhat, S., Merrick, W.C., Green, R., Shen, B., Liu, J.O., Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat. Chem. Biol. 6 (2010), 209–217.
44. Siegfried, N.A., Busan, S., Rice, G.M., Nelson, J.A.E., Weeks, K.M., RNA motif discovery by SHAPE and mutational profiling (SHAPE-MaP). Nat. Methods 11 (2014), 959–965.
45. Spadari, S., Sala, F., Pedrali-Noy, G., Aphidicolin: a specific inhibitor of nuclear DNA replication in eukaryotes. Trends Biochem. Sci. 7 (1982), 29–32.
46. Stout, E.P., Choi, M.Y., Castro, J.E., Molinski, T.F., Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies. J. Med. Chem. 57 (2014), 5085–5093.
47. Titov, D.V., Liu, J.O., Identification and validation of protein targets of bioactive small molecules. Bioorg. Med. Chem. 20 (2012), 1902–1909.
48. Titov, D.V., Gilman, B., He, Q.L., Bhat, S., Low, W.K., Dang, Y., Smeaton, M., Demain, A.L., Miller, P.S., Kugel, J.F., et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat. Chem. Biol. 7 (2011), 182–188.
49. Tornheim, K., O'Dell, R.G., Prosky, L., Effects of cycloheximide on DNA and protein synthesis in rat liver. Proc. Soc. Exp. Biol. Med. 131 (1969), 601–605.
50. Zubradt, M., Gupta, P., Persad, S., Lambowitz, A.M., Weissman, J.S., Rouskin, S., DMS-MaPseq for genome-wide or targeted RNA structure probing in vivo. Nat. Methods 14 (2017), 75–82.